LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/28/2019 |
| Start Date: | December 20, 2012 |
| End Date: | January 22, 2018 |
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
A single-arm, open-label, two-stage multicenter, phase II study. Patients were pre-screened
for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient
experienced unacceptable toxicity that precluded further treatment, discontinued treatment at
the discretion of the investigator or patient, started a new anticancer therapy and/or died.
LDK378 was continued beyond RECIST defined progressive disease (PD) as assessed by the
investigator, if in the judgment of the investigator, there was evidence of clinical benefit.
Patients who discontinued the study medication in the absence of progression continued to be
followed for tumor assessment until the time of PD as assessed by the investigator. Male and
female patients aged 18 or over with ALK-rearranged non-small cell cancer (NSCLC) were
screened for eligibility. Patients had to have received no prior crizotinib, and had to be
chemotherapy-naïve or been pretreated with cytotoxic chemotherapy (up to three prior lines).
for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient
experienced unacceptable toxicity that precluded further treatment, discontinued treatment at
the discretion of the investigator or patient, started a new anticancer therapy and/or died.
LDK378 was continued beyond RECIST defined progressive disease (PD) as assessed by the
investigator, if in the judgment of the investigator, there was evidence of clinical benefit.
Patients who discontinued the study medication in the absence of progression continued to be
followed for tumor assessment until the time of PD as assessed by the investigator. Male and
female patients aged 18 or over with ALK-rearranged non-small cell cancer (NSCLC) were
screened for eligibility. Patients had to have received no prior crizotinib, and had to be
chemotherapy-naïve or been pretreated with cytotoxic chemotherapy (up to three prior lines).
Key Inclusion criteria:
- Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that
carried an ALK rearrangement, as per the FDA-approved Vysis ALK break-apart FISH assay
(Abbott Molecular Inc.)
- Age 18 years or older at the time of informed consent.
- Patients must have NSCLC that had progressed during or after the last chemotherapy
regimen received prior to the first dose of LDK378, if chemotherapy was received
- Patients must have been chemotherapy-naive or had received 1-3 lines of cytotoxic
chemotherapy to treat their locally advanced or metastatic NSCLC
- Patients must have had a tumor tissue sample available, collected either at the time
of diagnosis of NSCLC or any time since.
- Patients must have recovered from all toxicities related to prior anticancer therapies
to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea
despite optimal supportive therapy who were not allowed to participate in the study.
Key Exclusion criteria:
- Prior treatment with crizotinib, or any other ALK inhibitor investigational agent, for
NSCLC
- Patients with known hypersensitivity to any of the excipients of LDK378.
- Patients with symptomatic central nervous system (CNS) metastases who were
neurologically unstable or had required increasing doses of steroids within the 2
weeks prior to study entry to manage CNS symptoms.
- History of carcinomatous meningitis.
- Presence or history of a malignant disease other than NSCLC that has been diagnosed
and/or required therapy within the past 3 years.
- Clinically significant, uncontrolled heart disease.
We found this trial at
5
sites
Click here to add this to my saved trials
Dallas, Texas 75390
Click here to add this to my saved trials
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
Click here to add this to my saved trials
Click here to add this to my saved trials